IS2756B - Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns - Google Patents

Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns

Info

Publication number
IS2756B
IS2756B IS8348A IS8348A IS2756B IS 2756 B IS2756 B IS 2756B IS 8348 A IS8348 A IS 8348A IS 8348 A IS8348 A IS 8348A IS 2756 B IS2756 B IS 2756B
Authority
IS
Iceland
Prior art keywords
synchronous
adjust
heterocyclic compounds
serotonin receptors
serotonin
Prior art date
Application number
IS8348A
Other languages
English (en)
Icelandic (is)
Other versions
IS8348A (is
Inventor
Nicholas I Carruthers
Wenying Chai
Xiaohu Deng
Curt A Dvorak
Annette K Kwok
Jimmy T Liang
Neelakandha Mani
Dale A Rudolph
Victoria D Wong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2756(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IS8348A publication Critical patent/IS8348A/is
Publication of IS2756B publication Critical patent/IS2756B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8348A 2003-09-17 2006-03-09 Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns IS2756B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11
PCT/US2004/030190 WO2005040169A2 (en) 2003-09-17 2004-09-15 Fused heterocyclic compounds as serotonin receptor modulators

Publications (2)

Publication Number Publication Date
IS8348A IS8348A (is) 2006-03-09
IS2756B true IS2756B (is) 2011-10-15

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8348A IS2756B (is) 2003-09-17 2006-03-09 Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns

Country Status (29)

Country Link
US (5) US7402680B2 (enExample)
EP (1) EP1668014B1 (enExample)
JP (1) JP5069907B2 (enExample)
KR (1) KR101151653B1 (enExample)
CN (1) CN103788089A (enExample)
AR (1) AR047218A1 (enExample)
AT (1) ATE420881T1 (enExample)
AU (1) AU2004283196B2 (enExample)
BR (1) BRPI0414541B8 (enExample)
CA (1) CA2539426C (enExample)
CL (1) CL2009000943A1 (enExample)
CR (1) CR8302A (enExample)
CY (1) CY1109416T1 (enExample)
DE (1) DE602004019118D1 (enExample)
DK (1) DK1668014T3 (enExample)
EA (2) EA200801812A1 (enExample)
EC (1) ECSP066436A (enExample)
ES (1) ES2319539T3 (enExample)
IL (2) IL174283A (enExample)
IS (1) IS2756B (enExample)
MX (1) MXPA06003150A (enExample)
NI (1) NI200600094A (enExample)
NZ (1) NZ545836A (enExample)
PL (1) PL1668014T3 (enExample)
PT (1) PT1668014E (enExample)
SG (1) SG146683A1 (enExample)
SI (1) SI1668014T1 (enExample)
TW (1) TWI345565B (enExample)
WO (1) WO2005040169A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545836A (en) 2003-09-17 2009-09-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
US20080161419A1 (en) * 2004-02-20 2008-07-03 Shinobu Akuzawa Prophylactic Antimigraine Agents
DK1778243T3 (da) * 2004-06-30 2013-02-04 Athersys Inc Substituerede azepinderivater som serotoninreceptormodulatorer
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1852129A4 (en) * 2005-02-08 2009-07-15 Astellas Pharma Inc REMEDIES FOR IRRITATION SYNDROME
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
BRPI0614397A2 (pt) * 2005-08-04 2011-03-29 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores de receptor de serotonina
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
KR20080044273A (ko) 2005-08-08 2008-05-20 아스텔라스세이야쿠 가부시키가이샤 아실구아니딘 유도체 또는 그의 염
CN101404882A (zh) * 2006-01-19 2009-04-08 阿特西斯公司 作为5-羟色胺5-HT2c受体配体的噻吩基和吡咯基氮杂类及其用途
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
DK2016064T3 (da) * 2006-05-05 2010-06-07 Janssen Pharmactuica N V Fremgangsmåder til fremstilling af pyrazolholdige forbindelser
ES2339822T3 (es) * 2006-08-28 2010-05-25 Actelion Pharmaceuticals Ltd. Derivados de 1,4,5,6,7,8-hexahidro-1,2,5-triaza-azuleno como antagonistas del receptor de orexina.
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
EP2229361A1 (en) * 2008-01-03 2010-09-22 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
BRPI0921058A2 (pt) 2008-11-18 2018-10-16 Hoffmann La Roche éteres alquilciclo-hexílicos de di-hidrotetra-azabenzoazulenos
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US8492374B2 (en) * 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
CN103492378B (zh) 2011-04-21 2016-09-28 巴斯夫欧洲公司 杀虫吡唑化合物
JP5796130B2 (ja) 2011-09-14 2015-10-21 プロクシマゲン リミテッド 新規な酵素阻害剤化合物
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
BR122019015104B1 (pt) 2012-06-20 2020-04-07 Basf Se mistura pesticida, composição, composição agrícola, métodos para o combate ou controle das pragas de invertebrados, para a proteção dos vegetais em crescimento ou dos materias de propagação vegetal, para a proteção de material de propagação vegetal e uso de uma mistura pesticida
PE20151139A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
AU2013364022A1 (en) 2012-12-21 2015-07-02 Abt Holding Company Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
CN107207513B (zh) * 2014-11-21 2020-07-28 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
WO2016130818A1 (en) * 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
WO2017175045A1 (en) * 2016-04-08 2017-10-12 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
US12509438B2 (en) * 2020-01-13 2025-12-30 Aptabio Therapeutics Inc. Pyrazole derivative
MD4097099T2 (ro) 2020-02-07 2025-02-28 Gasherbrum Bio Inc Agonişti GKP-1 heterociclici
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) * 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) * 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) * 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) * 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
KR0126300B1 (ko) 1992-12-28 1997-12-26 나이토 하루오 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체
US6677310B1 (en) * 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) * 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ES2223049T3 (es) 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
AU5317996A (en) 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
JP2000504677A (ja) 1996-02-09 2000-04-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) * 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
US6355642B1 (en) * 1996-06-28 2002-03-12 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US6177443B1 (en) * 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
WO1999024022A2 (en) 1997-11-10 1999-05-20 F. Hoffmann-La Roche Ag Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
CN1168716C (zh) * 1998-04-22 2004-09-29 明治制果株式会社 光学活性四氢苯并吲哚衍生物
EP0958824A3 (en) 1998-05-22 1999-12-01 Eli Lilly And Company Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
HRP20010716A2 (en) * 1999-04-01 2002-12-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
JP4703077B2 (ja) 1999-09-09 2011-06-15 クミアイ化学工業株式会社 ピリミジン誘導体及びそれを含有する除草剤
HK1049151A1 (zh) 1999-10-18 2003-05-02 Smithkline Beecham Plc 四氫化苯並吲衍生物、其製備方法和用作5-ht7受體拮抗劑的用途
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2003522178A (ja) 2000-02-04 2003-07-22 ワイス ピロロイソキノリンおよびテトラヒドロピロロイソキノリン誘導体ならびに５−ｈｔ７受容体の媒介物質としてのそれらの使用
WO2001068585A1 (en) 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
AU2001288706B2 (en) * 2000-09-06 2006-01-19 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
SK11612003A3 (sk) * 2001-02-21 2004-04-06 Janssen Pharmaceutica N. V. Izoxazolínové deriváty ako antidepresívne činidlá
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US6559174B2 (en) * 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) * 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
EP1441725A1 (en) * 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199544A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199542A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
MXPA04011956A (es) * 2002-05-30 2005-03-31 Vertex Pharma Inhibidores de proteinas cinasas jak y cdk2.
BR0311503A (pt) * 2002-06-20 2005-02-22 Lundbeck & Co As H Uso de um composto, uso de um agonista parcial, agonista inverso, ou antagonista de receptor de gabab, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto
BR0312924A (pt) * 2002-07-25 2005-07-12 Pharmacia Italia Spa Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos
JP2005537290A (ja) * 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
JPWO2004011467A1 (ja) 2002-07-29 2005-12-15 北興化学工業株式会社 トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
DE60318876T2 (de) 2002-10-30 2009-01-08 Ciba Holding Inc. Elektroluminezierende vorrichtung
CA2514656A1 (en) * 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
NZ545836A (en) * 2003-09-17 2009-09-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
US7652135B2 (en) * 2003-09-23 2010-01-26 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2004275777A1 (en) 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
AU2004296531A1 (en) 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
DE602005026169D1 (de) * 2004-12-17 2011-03-10 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
EP1899334B1 (en) * 2005-06-17 2008-09-24 Janssen Pharmaceutica N.V. Naphthyridine compounds
CA2612495A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
BRPI0614397A2 (pt) 2005-08-04 2011-03-29 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores de receptor de serotonina
EP1998620B1 (en) * 2006-03-10 2011-01-12 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
DK2016064T3 (da) * 2006-05-05 2010-06-07 Janssen Pharmactuica N V Fremgangsmåder til fremstilling af pyrazolholdige forbindelser
US20080045508A1 (en) * 2006-06-29 2008-02-21 Brett Allison Substituted aminomethyl benzamide compounds
JP2009544579A (ja) * 2006-06-29 2009-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換ベンジルアミン化合物
AU2007265239A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
WO2008064036A1 (en) * 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
JP5069907B2 (ja) 2012-11-07
DK1668014T3 (da) 2009-04-20
IL209082A0 (en) 2011-01-31
KR20070023633A (ko) 2007-02-28
US20090270370A1 (en) 2009-10-29
US20110040088A1 (en) 2011-02-17
ECSP066436A (es) 2006-09-18
IL174283A (en) 2012-06-28
EA200600433A1 (ru) 2006-08-25
US20080103132A1 (en) 2008-05-01
SG146683A1 (en) 2008-10-30
CR8302A (es) 2008-09-10
KR101151653B1 (ko) 2012-06-28
AR047218A1 (es) 2006-01-11
AU2004283196B2 (en) 2011-08-25
BRPI0414541B1 (pt) 2019-02-26
NZ545836A (en) 2009-09-25
EP1668014B1 (en) 2009-01-14
US8618288B2 (en) 2013-12-31
US7402680B2 (en) 2008-07-22
IS8348A (is) 2006-03-09
MXPA06003150A (es) 2006-08-31
EA200801812A1 (ru) 2009-06-30
ES2319539T3 (es) 2009-05-08
EA010905B1 (ru) 2008-12-30
JP2007505908A (ja) 2007-03-15
US7897771B2 (en) 2011-03-01
CA2539426C (en) 2012-07-10
SI1668014T1 (sl) 2009-06-30
TWI345565B (en) 2011-07-21
ATE420881T1 (de) 2009-01-15
IL174283A0 (en) 2006-08-01
CL2009000943A1 (es) 2009-08-21
BRPI0414541A (pt) 2006-11-07
EP1668014A2 (en) 2006-06-14
US20100016281A1 (en) 2010-01-21
CA2539426A1 (en) 2005-05-06
PT1668014E (pt) 2009-03-17
US7579470B2 (en) 2009-08-25
CN103788089A (zh) 2014-05-14
CY1109416T1 (el) 2014-08-13
NI200600094A (es) 2014-02-25
DE602004019118D1 (de) 2009-03-05
AU2004283196A1 (en) 2005-05-06
BRPI0414541A8 (pt) 2019-01-02
PL1668014T3 (pl) 2009-06-30
BRPI0414541B8 (pt) 2021-05-25
TW200521123A (en) 2005-07-01
HK1118550A1 (en) 2009-02-13
US20050119295A1 (en) 2005-06-02
WO2005040169A2 (en) 2005-05-06
WO2005040169A3 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
IS2756B (is) Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns
IS2905B (is) Afleiður (þíó) karbamóýl-sýklóhexans sem mótlyf D3/D2 viðtaka
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
EP1752457A4 (en) CONDENSED HETEROCYCLIC COMPOUND
FR14C0045I2 (fr) Nouveau derive de 2-pyridylethylbenzamide
IS8466A (is) 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka
ZA200700683B (en) Piperidine derivatives as histamine H3 receptor ligands
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
IL183665A0 (en) Heterocyclic compounds as ccr2b antagonists
EP1689389A4 (en) INDOLE COMPOUNDS
ATE415385T1 (de) Hexafluorisopropanolsubstituierte etherderivate
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
IL183647A (en) The heterocyclic compounds are converted into 3-ethylidenehydrazino
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
NO20070299L (no) Novel heterocyclic compounds
ITMI20042238A1 (it) Composti per fluoropolirterei
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
NO20055758D0 (no) Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
ZA200705159B (en) Heterocyclic compounds as CCR2B antagonists
ITMI20042203A1 (it) Macchina per la vibro-burattatura
SE0400022D0 (sv) New compounds
IS8552A (is) Formamíð afleiður gagnlegar sem adrenalín viðtaki